{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=85", "query": { "condition": "Melanoma Neoplasms", "page": 85 }, "page_size": 10 }, "pagination": { "page": 85, "page_size": 10, "total_count": 2209, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=86&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma+Neoplasms&page=84&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T00:45:47.899Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01820364", "title": "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "LGX818", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2013-11", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01820364" }, { "nct_id": "NCT00587964", "title": "Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastasis", "Bladder Cancer", "Breast Cancer", "Cervical Cancer", "Colon Cancer", "HEENT Cancer", "Lung Cancer", "Melanoma", "Pancreatic Cancer", "Prostate Cancer", "Rectal Cancer", "Sarcoma", "Testicular Cancer" ], "interventions": [ { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2004-06", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2016-02-22", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00587964" }, { "nct_id": "NCT06626516", "title": "Tebentafusp-tebn With LDT in Metastatic UM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "Tebentafusp-Tebn", "type": "DRUG" }, { "name": "GM-CSF (Sargramostim)", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2025-10-15", "completion_date": "2032-08", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06626516" }, { "nct_id": "NCT05557045", "title": "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Solid Tumor", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Anaplastic Thyroid Cancer (ATC)" ], "interventions": [ { "name": "JZP815", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2022-10-10", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 15, "location_summary": "Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557045" }, { "nct_id": "NCT01621295", "title": "Assessing the Patient Experience in Cancer Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain Neoplasm", "Breast Neoplasm", "Endocrine Gland Neoplasm", "Gastrointestinal Neoplasm", "Genitourinary Neoplasm", "Gynecological Neoplasm", "Head and Neck Neoplasm", "Lung Neoplasm", "Melanoma", "Sarcoma" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 408, "start_date": "2012-05", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 3, "location_summary": "Los Angeles, California • Rochester, Minnesota", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01621295" }, { "nct_id": "NCT00351728", "title": "Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ocular Melanoma", "Choroidal Melanoma", "Uveal Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2006-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2016-07-07", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00351728" }, { "nct_id": "NCT05266430", "title": "Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Choroidal Melanoma", "Indeterminate Lesions" ], "interventions": [ { "name": "Standard of Care", "type": "OTHER" }, { "name": "AU-011", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Aura Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2022-04-14", "completion_date": "2023-04-20", "has_results": false, "last_update_posted_date": "2023-08-09", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 7, "location_summary": "Royal Oak, Michigan • Portland, Oregon • Greenville, South Carolina + 4 more", "locations": [ { "city": "Royal Oak", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Bellaire", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05266430" }, { "nct_id": "NCT05039801", "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Endometrial Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Clear Cell Adenocarcinoma", "Chondrosarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Melanoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Stage III Ovarian Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Glutaminase-1 Inhibitor IACS-6274", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-30", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039801" }, { "nct_id": "NCT05047536", "title": "KZR-261 in Subjects With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumor" ], "interventions": [ { "name": "KZR-261", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kezar Life Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2021-09-30", "completion_date": "2025-01-17", "has_results": true, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 12, "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05047536" }, { "nct_id": "NCT03057327", "title": "Promoting Early Detection of Melanoma During the Mammography Experience", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma (Skin Cancer)" ], "interventions": [ { "name": "Improve awareness of checking moles", "type": "BEHAVIORAL" }, { "name": "Comparator", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 560, "start_date": "2017-03-01", "completion_date": "2017-07-27", "has_results": false, "last_update_posted_date": "2017-10-09", "last_synced_at": "2026-11-05T00:45:47.899Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03057327" } ] }